SECONDARY MYELODYSPLASTIC SYNDROME
Clinical trials for SECONDARY MYELODYSPLASTIC SYNDROME explained in plain language.
Never miss a new study
Get alerted when new SECONDARY MYELODYSPLASTIC SYNDROME trials appear
Sign up with your email to follow new studies for SECONDARY MYELODYSPLASTIC SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Early trial aims to boost immune system to fight tough blood cancers
Disease control OngoingThis early-stage study is testing the safety and best dose of a two-drug combination for people with aggressive forms of blood cancer (myelodysplastic syndrome or acute myeloid leukemia) that have returned or not responded to prior treatments. The trial combines a chemotherapy dr…
Matched conditions: SECONDARY MYELODYSPLASTIC SYNDROME
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New transplant strategy aims to tame tough blood cancers
Disease control OngoingThis study is testing a two-drug chemotherapy regimen followed by a donor stem cell transplant for adults with certain blood cancers that are in remission or at high risk. The goal is to see if this approach can better control the disease and prevent it from coming back after the…
Matched conditions: SECONDARY MYELODYSPLASTIC SYNDROME
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New drug combo targets rare, Tough-to-Treat cancer caused by prior therapy
Disease control OngoingThis study is testing whether two drugs, venetoclax and azacitidine, work better together to treat a specific type of bone marrow cancer called therapy-related myelodysplastic syndrome (t-MDS). This cancer can develop after a person has received chemotherapy or radiation for a pr…
Matched conditions: SECONDARY MYELODYSPLASTIC SYNDROME
Phase: PHASE2 • Sponsor: Uma Borate • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC